SQZ Biotechnologies Debt to Equity Ratio 2020-2023 | SQZ

Current and historical debt to equity ratio values for SQZ Biotechnologies (SQZ) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. SQZ Biotechnologies debt/equity for the three months ending March 31, 2023 was 0.00.
SQZ Biotechnologies Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2023-03-31 $0.03B $0.04B 0.82
2022-12-31 $0.04B $0.06B 0.75
2022-09-30 $0.09B $0.07B 1.26
2022-06-30 $0.09B $0.09B 1.05
2022-03-31 $0.10B $0.11B 0.91
2021-12-31 $0.10B $0.12B 0.82
2021-09-30 $0.11B $0.13B 0.83
2021-06-30 $0.09B $0.15B 0.56
2021-03-31 $0.09B $0.17B 0.55
2020-12-31 $0.10B $0.13B 0.82
2020-09-30 $0.11B $0.07B 1.52
2020-06-30 $0.00B $0.00B 0.00
2020-03-31 $0.00B $0.00B 0.00
2019-12-31 $0.00B 0.00
2019-09-30 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.017B $0.021B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $138.614B 8.47
GSK (GSK) United Kingdom $70.187B 9.79
Bio-Rad Laboratories (BIO.B) United States $10.988B 29.38
QIAGEN (QGEN) Netherlands $10.454B 22.07
Ginkgo Bioworks Holdings (DNA) United States $3.441B 0.00
Arcus Biosciences (RCUS) United States $1.502B 0.00
Biohaven (BHVN) United States $1.477B 0.00
Emergent Biosolutions (EBS) United States $0.399B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.200B 0.00
Enzo Biochem (ENZ) United States $0.110B 0.00